Long COVID and its associated factors among COVID survivors in the community from a middle-income country – an online cross-sectional study
=============================================================================================================================================

* Foong Ming Moy
* Noran Naqiah Hairi
* Eugene Ri Jian Lim
* Awang Bulgiba

## Abstract

**Introduction** Patients with COVID-19 usually recover and return to normal health, however some patients may have symptoms that last for weeks or even months after recovery. This persistent state of ill health is known as Long COVID if it continues for more than 12 weeks and are not explained by an alternative diagnosis. Long Covid has been overlooked in low and middle income countries. Therefore, we conducted an online survey among the COVID-19 survivors in the community to explore their Long COVID symptoms, factors associated with Long COVID and how Long COVID affected their work.

**Methods** This was a cross sectional study conducted from July to September 2021, during the implementation of a nationwide movement control order (MCO). Data was collected using the REDCap electronic data capture tool. The questionnaire was distributed in social and news media. The questionnaire covers information such as socio-demographic characteristics, existing comorbidities, self-perception on health, information on the acute COVID-19 condition and treatment received, symptoms and duration of post-COVID condition and effects on occupation. Results: A total of 732 COVID-19 survivors responded. There were slightly more females (58.7%), younger and more highly educated respondents. More than half of them were overweight or obese and about two third were free of comorbidities. Among these respondents, about 56% were without or with mild symptoms during their acute COVID-19 conditions. A total of 21.1% of the respondents reported to experience Long COVID. The most commonly reported symptoms for Long COVID were fatigue, brain fog, depression, anxiety, insomnia, arthralgia or myalgia. Females had 58% higher odds (95% CI: 1.02, 2.45) of experiencing Long COVID. Patients with moderate and severe levels of acute COVID-19 symptoms had OR of 3.01 (95% CI: 1.21, 7.47) and 3.62 (95% CI: 1.31, 10.03) respectively for Long COVID.

**Conclusion** This study provides additional insight on the symptoms and duration of post-COVID symptoms as well as the associated factors with Long COVID among COVID-19 survivors in Malaysia. Recognition of Long COVID and its associated factors is important in planning prevention, rehabilitation, clinical management to improve recovery and long-term COVID-19 outcomes.

## Introduction

As of March 2022, Malaysia, a middle-income country has had more than 3 million individuals infected with COVID-19 with 32 thousand deaths since March 2020. While most patients with COVID-19 recover and return to normal health, some patients may have symptoms that last for weeks or even months after recovery from COVID-19. These patients are not infectious to others during this time. This persistent state of ill health is known as Long COVID or post COVID condition if it continues for more than 12 weeks and are not explained by an alternative diagnosis (1).

Patients with Long COVID reported experiencing different combinations of symptoms such as fatigue, dyspnoea, cough, anxiety, cognitive impairment, myalgia, symptoms that get worse after physical activities (2, 3). These symptoms could be driven by a direct effect of virus infection and might be explained by several hypotheses including aberrant immune response, hyperactivation of the immune system, or autoimmunity (4). Additionally, indirect effects including reduced social contact, loneliness, incomplete recovery of physical health, and loss of employment could affect psychiatric symptoms(5).

Preliminary results from a national survey in the UK estimates that around 1 in 10 COVID-19 patients exhibit symptoms for a period of 12 weeks or longer (6). Another study found that 30% of COVID-19 patients surveyed still had persistent symptoms after nine months (7). This has become an increasing concern. Most patients had good physical and functional recovery during follow-up, and the majority of them who were employed before COVID-19 had returned to their original work. However, some may still experience poorer work performance due to the Long COVID sequalae (4, 5).

Studies on Long Covid were mainly conducted in Europe and on patients recently discharged from hospitals. A living systematic review identified limited evidence from low to middle-income countries and among people who were not hospitalized (3). In Malaysia, Long Covid has been overlooked and less emphasis has been given to the issue. There is a scarcity of findings on Long COVID. To date, there are only some preliminary findings among COVID-19 survivors, reported by the Ministry of Health Malaysia. Based on the Sungai Buloh COVID-19 Rehabilitation Outpatient Specialized Services databases, after 12 weeks of acute COVID-19, 474 (63.6%) out of 745 COVID-19 survivors experienced Post COVID-19 syndrome. The five most commonly reported symptoms were fatigue (73.4%); exertional dyspnoea (19.4%); insomnia (13.9%); cough (9.7%) and pain (7.3%). However, psychological symptoms such as anxiety, depression and stress were not reported. In addition, information on whether COVID-19 survivors who experienced milder symptoms or those not admitted to hospitals experienced any Long COVID symptoms and what are the factors associated with Long COVID are not available. Therefore, we conducted an online survey among the COVID-19 survivors in the community to explore their Long COVID symptoms, factors associated with Long COVID and how Long COVID affected their work.

## Methods

This was a cross sectional study conducted from July to September 2021, during the implementation of a nationwide movement control order (MCO) or lockdown. Data was collected using an online questionnaire, the REDCap electronic data capture tools hosted at our university (University of Malaya). REDCap (Research Electronic Data Capture) (8, 9) is a secure, web-based software platform designed to support data capture for research studies, providing a) an intuitive interface for validated data capture; b) audit trails for tracking data manipulation and export procedures; c) automated export procedures for seamless data downloads to common statistical packages; and d) procedures for data integration and interoperability with external sources.

The questionnaire was prepared in English, and translated into the Malay and Chinese languages to cater to the multiethnic population. It was distributed in social media, COVID-19 support group webpage, news media in the above-mentioned languages with the aim of reaching as many COVID-19 patients as possible. The questionnaire was anonymous and identifiable information such as names, telephone numbers and emails were not collected. However, respondents were given a choice to if they wanted to be contacted (to leave their emails) if the researchers found their responses to be in need of referral for further attention, or for follow up with additional activities or assistance required.

Ethics clearance was obtained from the University Malaya Research Ethics Committee (Reference number: UM.TNC2/UMREC_1439). Informed consent was obtained before data collection. The questionnaire covers information such as socio-demographic characteristics, existing comorbidities, self-perception on health, information on the acute COVID-19 condition and treatment received, symptoms and duration of post-COVID condition, effects on occupation and mental health status.

Data from RedCap were exported into the SPSS version 23 software for data analysis. Mean with standard deviation (SD) or median with inter-quartile range (IQR) was used to report normally distributed or skewed data respectively. Frequency with percentage was used to present categorical variables. Univariable and multivariable logistic regression analyses were carried out to determine the factors associated with Long COVID. Variables with *p* values < 0.25 or clinically important variables were included in the final model. Significance level was preset at *p* < 0.05.

## Results

A total of 732 COVID survivors responded in the online survey. There were slightly more females (58.7%) who responded (Table 1). More than 60% of the respondents were in the twenties and thirties with tertiary education levels (Degree and above). Two third of the respondents resided in the Central region of Peninsular Malaysia. More than half of them were overweight or obese. About 74% of them were free of comorbidities. Majority of them were working. Only one quarter of them had full vaccination at the time of survey.

View this table:
[Table 1:](http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272168/T1)

Table 1: 
Socio-demographic characteristics, Body Mass Index (BMI), vaccination status and medical history of respondents

Among these respondents, about 56% were without or with mild symptoms during their acute COVID-19 conditions (Table 2). Almost half of them were on home quarantine, with the others admitted to the COVID-19 centres or hospitals. Among those hospitalised, 20% required the use of ventilators while another 23% were admitted to Intensive Care Units (ICU). The mean duration of hospital stay was 10.9+8.2 days with a minimum of 2 days and maximum of 52 days. The mean duration since the diagnosis of COVID-19 was 27.3 + 12.5 weeks, with more than 95% were diagnosed at least 3 months ago.

View this table:
[Table 2:](http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272168/T2)

Table 2: 
Acute COVID-19 information of respondents

Post-COVID symptoms were experienced at different durations. Cumulatively, approximately 88% experienced post-COVID symptoms up to 6 weeks since diagnosis, 48% more than 6 weeks, 21.1% more than 3 months (Long COVID) and 10% more than 6 months. Figure 1 presents the common symptoms reported over the duration mentioned. The most commonly reported symptoms for Long COVID (more than 3 months) were fatigue, brain fog, depression, anxiety, insomnia, arthralgia or myalgia. These commonly reported symptoms are similar at duration up to 6 weeks and more than 6 weeks.

![Figure 1.](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2022/03/12/2022.03.09.22272168/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272168/F1)

Figure 1. 
Post COVID symptoms at different duration

Among those working, one third of them reported that their work performance was affected with majority of them (73%) reduced their working hours, while some (23.9%) had to take leave or even resign from their jobs (3%). Only 67.5% of them perceived to be in good health currently compared to before they were infected with COVID-19 (92.9%) (Table 3).

View this table:
[Table 3:](http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272168/T3)

Table 3: 
Perceived health and work productivity among Long COVID respondents

At univariate level, only severity of acute COVID-19 was significantly associated with Long COVID; while sex and comorbidities were marginally associated; age groups and BMI categories were not associated with Long COVID (Table 3). In the multivariable models, females were found to have 58% higher odds of experiencing Long COVID. Patients with moderate and severe levels of acute COVID-19 had OR of 3.01 (95% CI: 1.21, 7.47) and 3.62 (95% CI: 1.31, 10.03) respectively for Long COVID (Table 4).

View this table:
[Table 4:](http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272168/T4)

Table 4: 
Factors associated with Long COVID

## Discussion

As we used an online questionnaire to collect data, the respondents were younger and with higher education levels. Almost two-thirds were from the central region of Peninsular Malaysia, the most progressive states, with high population density and where the capital city is situated. Older individuals and those with lower education levels were under-represented. There were also slightly more females who responded to the study, similarly found from other studies with more female participation (10).

The prevalence of comorbidities such as hypertension, diabetes mellitus among the respondents was low as more than half of them were in their thirties and forties. About two third of them were free of comorbidities. Majority of them worked as only 18% of them were in their sixties. However, their BMI status was comparable with the national statistics (11) where half of them were overweight or obese. As our survey was conducted before vaccination was widely available, only one quarter of them reported to be fully vaccinated at the time of survey. However, we were unable to ascertain if the respondents were vaccinated before or after the diagnosis of COVID-19. Hence, the effect of vaccination on Long COVID symptoms or duration was not studied.

According to the COVID-19 Management Guidelines (12), the confirmed COVID-19 patients in Malaysia are classified and explicitly managed based on five categories: stage 1 (asymptomatic), stage 2 (symptomatic without pneumonia), stage 3 (symptomatic with pneumonia), stage 4 (symptomatic with pneumonia and require supplemental oxygen), and stage 5 (critically ill with multi-organ involvement). Based on the meta-analysis by Ng et al (13) on the prevalence rates of the clinical stages of COVID-19 in Malaysia: 27.8% of the patients were asymptomatic (stage 1), 32% mild (stage 2), 17% moderate (stage 3) and 11% severe (stage 4 and 5). However, only 11% of our respondents were asymptomatic and about one third of our respondents were in the moderate categories. This observed difference may be due to volunteer bias where those in more severe COVID condition were more likely to respond as they may want to report their experiences. We did not report our findings using the 5-stage categories as high proportion of our respondents could not recall this information.

Twenty one percent of our respondents reported to have experienced Long COVID. In another cohort study among hospitalized patients, 76% of patients reported at least one symptom at 6 months after acute COVID-19(14). According to a retrospective cohort study using linked electronic health records (EHRs) data of 273,618 COVID-19 survivors, one in three patients had one or more symptoms of long-COVID recorded between 3 and 6 months after a diagnosis of COVID-19 (15). In another systematic review among patients with mild COVID-19 infection(16), they were reported to experience persistent symptoms after three weeks with the frequency between 10% to 35%. The difference in this reported prevalence maybe influenced by the variety of definitions of Long COVID, study settings and characteristics of patients.

The most commonly experienced symptoms were fatigue, brain fog, depression, anxiety, insomnia, arthralgia or myalgia, which are similarly reported in systematic reviews on Long COVID (3, 17). The Long COVID symptoms’ aetiology is complex, and several mechanisms might be responsible for these variety of symptoms. It appears that persistent inflammation plays a key role in the pathogenesis of Long COVID symptoms. In a study among patients who experienced fatigue, cognitive decline, and apathy after recovering from Covid-19, researchers discovered an increased amount of cytokines in the blood, particularly interleukin-6 (IL-6), which alters neuronal function as it passes through the blood-brain barrier, resulting in neurological complications of Long COVID.(18)

Covid-19 is also shown to be neurotropic, which contributes to a higher occurrence of neurological symptoms as it invades the central nervous system. Damage to the brainstem, which has limited regeneration capacity, might lead to long-term cardiorespiratory and neurological repercussions, which could be the cause of long-term COVID symptoms.(19) Depression is also found to have an association with IL-6, regardless of other factors of depression that occurred during the COVID-19 pandemic.

Other than inflammation, Long COVID fatigue could be caused by lung dysfunction. This owes to the acute viral infection that initiated the inflammatory response, which subsequently caused fibrosis to the lungs. The severity of the fibrosis would manifest a spectrum of clinical manifestations such as fatigue, cognitive symptoms and breathlessness. (20) As the gut plays a role in controlling the body’s immune system, gut microbial dysfunction has also been linked to gastrointestinal and neurological symptoms of Long COVID.(21)

Anxiety, depression and stress were reported by a great proportion of our respondents. This could be due to their worries about their delayed recovery. The aetiology of the psychiatric consequences of COVID-19 infection is likely to be multifactorial and might include the direct effects of viral infection, cerebrovascular disease, the degree of physiological compromise, the immunological response, medical interventions, social isolation, the psychological impact of the severe and potentially fatal COVID-19, concerns about infecting others, and stigma (5). The link between inflammation with increased concentrations of C-reactive protein, ferritin, and interleukin-6; with depression might also explain some of the psychiatric morbidity (22).

Due to the post-COVID symptoms, respondents who were working reported that their work performance or productivity was affected, where they had to reduce their working hours or take leave. Davis et al (23) reported that 45.2% of their Long COVID participants required a reduced work schedule compared to pre-illness, and an additional 22.3% were not working at the time of survey due to illness. Aiyegbusi et al also reported that those who were working before getting infected were unable to return to work due to chronic symptoms, while those who were able to return to work had to modify their responsibilities or cut their working hours due to health concerns, and there are also those who were previously hospitalized that were unable to return to work (24). Symptoms like brain fog or difficult to concentrate may affect the work performance of those working in the education or accounting sectors. These affected individuals may take longer time to return to their original level of performance. Being lethargic may reduce their work performance. Employers and their fellow colleagues should be more empathetic with their situation and provide support when required.

Based on previous literature, sex, BMI categories, comorbidities and severity of acute COVID-19 were reported to be associated with Long COVID (3, 19, 25). However, we only found sex and severity of acute COVID-19 to be significantly associated with Long COVID. Females had 58% higher odds of getting Long COVID, as reported elsewhere (15, 26). According to the autoimmune hypothesis, females have stronger immune response than males due to genetic and hormonal factors. This contributes to a more active immune response where activation of white blood cells, production of inflammatory markers and antibodies are stronger than males. This could be seen as a double-edged sword as it appears protective towards severe symptoms and deaths from COVID-19, but it could bring about the emergence of autoimmune inflammatory symptoms in Long COVID (27).

It should be noted that 10 to 17% of our respondents without symptoms or with mild symptoms experienced Long COVID. The available evidence on the occurrence of post-COVID symptoms in individuals with mild Covid-19 infection is minimal. The majority of patients with mild COVID infections are usually treated as outpatients at home or in clinics, with minimal care devoted in comparison to those who are admitted to the hospital with serious infections (16). Therefore, the post-COVID or Long COVID symptoms may not be captured by the health authorities if the patients did not seek treatment. These patients should be educated on Long COVID symptoms and to seek treatment if needed. The Ministry of Health Malaysia has a protocol on the management of Long COVID for the primary health care facilities (28). With that, it is hope that the primary care physicians will take appropriate action among COVID-19 survivors who reported post-COVID symptoms.

On the other hand, respondents who had moderate to severe acute COVID-19 condition had higher (3.0 to 3.6 times) odds of experiencing Long COVID, compared to those without symptoms. Similar results are reported by Taquet at al (15). This relationship may be explained by the immune response to the SARS-CoV-2 virus which stimulates the production of cytokines and other inflammatory mediators, with higher concentrations found in those with a more severe COVID-19 (26). The multi-systemic inflammatory response to the virus may also be responsible for persistent COVID-19 symptoms in survivors (29, 30).

The prevalence of Long COVID increased with age, almost doubling the prevalence of Long COVID for those more than 70 years old compared to those 18 to 49 years old (31). As an individual ages, one’s ability to manage viral load also deteriorates with age. The inflammatory process may be maladaptive, causing immune system hyperactivation and small blood vessel hypercoagulation, contributing to multi-system involvement in Long COVID(32). However, age group was not found to be associated with Long COVID in our study as most of our respondents were young, probably the senior citizens may not be well versed in technology and could not take part in our study since we used a self-reported online questionnaire.

Being overweight or obese predisposed to post-COVID symptoms. Obese COVID survivors usually take longer time to resolve abnormalities on chest radiographs, which is linked to symptoms of Long COVID, such as fatigue, cognitive decline and shortness of breath etc (33-35). These obese COVID survivors may have clustering of risk factors such as old age with multiple comorbidities. However, we did not find an association between BMI categories with Long COVID, probably our sample were young and with lower rates of comorbidities.

Some studies showed no correlation between the prolonged COVID symptoms and comorbidities of patients (25, 33), similar with our findings. However, comorbidities such as hypertension, diabetes and dyslipidemia could be indirect risk factors to Long COVID as they are commonly associated with obesity that might increase the likelihood of Long COVID(25, 34).

While interpreting the results, there are some limitations that need to be addressed. First, this is a cross sectional study where respondents were asked to recall their symptoms and duration of experience. This may subject to recall bias and it is impossible to retrospectively confirm the length of COVID-19 related symptoms. In order to overcome these issues, a prospective cohort study may be a better study design. We also did not assess whether the symptoms reported were intermittent or continuous for the entire three or six months.

Next, selection bias cannot be avoided in an online study as younger, more highly educated and tech-savvy individuals were more likely to respond. Therefore, our respondents may not be fully representative of the general population.

We could not ascertain the effect of vaccination on Long COVID. Some studies suggested that vaccination may lead to potentially lower prevalence of Long Covid (36). This should be explored in future studies.

The definition of Long COVID used in the current study may be different from the latest definition proposed by WHO on the 6 October 2021 (37). The latest definition defines Long COVID or Post COVID-19 condition as condition that occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. The difference between the two definitions is that the symptoms should last for at least 2 months, which is missing from the earlier definition. However, this cannot be rectified as our study was completed before the new definition was announced.

The pathophysiology and mechanism behind the persistence of symptoms or Long Covid has yet to be identified as researchers are still trying to learn and understand about COVID-19 which is a new disease and Long COVID, an even newer condition. To our knowledge, this represents the first study to describe the symptoms, duration and associated factors of Long COVID in Malaysia. With over 3 million COVID 19 positive cases in Malaysia at the time of writing, and with numbers likely to increase due to the Omicron variant, the number of survivors with Long COVID will continue to increase. This could have significant and lasting health and economic consequences for the country. Our findings can help in improve planning for the use of relevant healthcare resources.

## Conclusion

This study provides additional insight on the symptoms and duration of post-COVID symptoms as well as the associated factors with Long COVID among COVID-19 survivors in Malaysia. Recognition of Long COVID and its associated factors is important in planning prevention, rehabilitation, clinical management to improve recovery and long-term COVID-19 outcomes. With recurrent and repeated COVID-19 infections, a more comprehensive investigation is necessary to understand the impact of Long COVID.

## Data Availability

All data produced in the present study are available upon reasonable request to the authors

## Conflict of Interest

The authors declare no conflict of interest.

## Acknowledgement

The authors would like to thank the respondents in sharing their experience in the study. The support from the University Malaya is acknowledged. This study is part of the COVID-19 Epidemiological Analysis and Strategies (CEASe) Project with funding from the Ministry of Science, Technology and Innovation (UM.0000245/HGA.GV).

*   Received March 9, 2022.
*   Revision received March 9, 2022.
*   Accepted March 12, 2022.


*   © 2022, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## References

1.  1.National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline; [https://www.nice.org.uk/guidance/ng188](https://www.nice.org.uk/guidance/ng188). 2020.
    
    

2.  2.Organization. WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance 2020.
    
    

3.  3.Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NToiYm1qZ2giO3M6NToicmVzaWQiO3M6MTE6IjYvOS9lMDA1NDI3IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjIvMDMvMTIvMjAyMi4wMy4wOS4yMjI3MjE2OC5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 

4.  4.Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–64.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

5.  5.Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–27.
    
    

6.  6.The prevalence of long COVID symptoms and COVID-19 complications. (last updated: 16 December 2020) 2020.
    
    

7.  7.Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2):e210830.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jamanetworkopen.2021.0830&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33606031&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

8.  8.Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jbi.2019.103208&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=31078660&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

9.  9.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jbi.2008.08.010&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=18929686&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000264958800018&link_type=ISI) 

10. 10.SR P, ME W. Non-response in student surveys: the role of demographics, engagement and personality Res High Educ. 2005;46(2):127–52.
    
    

11. 11.Institute for Public Health. National Health and Morbidity Survey (NHMS) 2019: Non-communicable diseases, healthcare demand, and health literacy—Key Findings. Putrajaya; 2020.
    
    

12. 12.Ministry of Health Malaysia. COVID-19 Management Guidelines (Annex 2e). 2020. p. Available from: <[https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX\_2e\_CLINICAL\_MANAGEMENT\_OF\_CONFIRMED\_COVID>-\_CASE\_IN\_ADULT\_AND\_PAEDIATRIC\_13082021.pdf](https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX\_2e\_CLINICAL\_MANAGEMENT\_OF\_CONFIRMED\_COVID>-\_CASE\_IN\_ADULT_AND_PAEDIATRIC_13082021.pdf).
    
    

13. 13.Ng JW, Chong ETJ, Tan YA, Lee HG, Chan LL, Lee QZ, et al. Prevalence of Coronavirus Disease 2019 (COVID-19) in Different Clinical Stages before the National COVID-19 Vaccination Programme in Malaysia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(4):2216.
    
    

14. 14.Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England). 2021;397(10270):220–32.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(20)32656-8&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

15. 15.Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773–e.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1003773&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

16. 16.van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2021:cmab076.
    
    

17. 17.Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin Microbiol Infect. 2022:S1198-743X(22)00038-6.
    
    

18. 18.Ortelli P, Ferrazzoli D, Sebastianelli L, Engl M, Romanello R, Nardone R, et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J Neurol Sci. 2021;420:117271–.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.jns.2020.117271&link_type=DOI) 

19. 19.Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737–54.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/23744235.2021.1924397&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34024217&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

20. 20.Maltezou HC, Pavli A, Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021;9(5):497.
    
    

21. 21.Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121–41.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.cell.2014.03.011&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24679531&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000333968900012&link_type=ISI) 

22. 22.Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nature reviews Neuroscience. 2016;17(8):497–511.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/nrn.2016.69&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=27277867&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

23. 23.Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

24. 24.Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. Symptoms, complications and management of long COVID: a review. Journal of the Royal Society of Medicine. 2021;114(9):428–42.
    
    

25. 25.Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. MedRxiv. 2021.
    
    

26. 26.Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6Mzoic2NpIjtzOjU6InJlc2lkIjtzOjEyOiIzNjgvNjQ5MC80NzMiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMi8wMy8xMi8yMDIyLjAzLjA5LjIyMjcyMTY4LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 

27. 27.Dupuis ML, Maselli A, Pagano MT, Pierdominici M, Ortona E. Immune response and autoimmune diseases: a matter of sex. Italian Journal of Gender-Specific Medicine. 2019;5(1):11–20.
    
    

28. 28.Ministry of Health Malaysia. Post COVID-19 Management Protocol (First Edition). Putrajaya; 2021.
    
    

29. 29.Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. 2020;55:102763.
    
    

30. 30.Sollini M, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Gelardi F, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging. 2021;48(5):1460–6.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00259-020-05084-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33123760&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

31. 31.Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626–31.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2022%2F03%2F12%2F2022.03.09.22272168.atom) 

32. 32.Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020;12(10):9959–81.
    
    

33. 33.Vimercati L, De Maria L, Quarato M, Caputi A, Gesualdo L, Migliore G, et al. Association between Long COVID and Overweight/Obesity. J Clin Med. 2021;10(18):4143.
    
    

34. 34.Fernández-de-las-Peñas C, Torres-Macho J, Elvira-Martínez CM, Molina-Trigueros LJ, Sebastián-Viana T, Hernández-Barrera V. Obesity is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: A multicentre case-control study. International Journal of Clinical Practice. 2021;75(12):e14917.
    
    

35. 35.Aminian A, Bena J, Pantalone KM, Burguera B. Association of obesity with postacute sequelae of COVID-19. Diabetes, Obesity and Metabolism. 2021;23(9):2183–8.
    
    

36. 36.Venkatesan P. Do vaccines protect from long COVID? Lancet Respir Med. 2022;10(3):E30.
    
    

37. 37.World Health Organisation. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. 2021.